Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment reporting

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07026474Phase 3Recruiting

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

Role: lead

NCT05433116Phase 2Active Not Recruiting

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Role: lead

NCT06223711Phase 2Recruiting

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Role: lead

SYFf37a3ca38c3044c39a038324552706c2Phase 2Unknown

Inducta

Role: lead

All 4 trials loaded